Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets.

Interferon-gamma (IFN-gamma) produced by lesional T cell clones is critical for the induction into G1 of the cell cycle by psoriatic keratinocyte stem cells; however, direct data demonstrating psoriatic lesional T cell subset IFN-gamma expression, and quantitation at a single cell level to calculate in vivo proportions, are lacking. In this study, using flow cytometry of freshly isolated normal and psoriatic lesional T cells from keratome biopsies, we found elevated CD3+, CD4+, and CD8+ T cells in all compartments of psoriatic skin, compared with normals. Using Brefeldin A to induce short-term intracellular accumulation of IFN-gamma in T cells capable of IFN-gamma production, we found that 90% of psoriatic patients have IFN-gamma-producing T cells at a greater proportion of their CD3+ cells than normals, with a mean of 16%+/-3%, as compared with 4%+/-2% in normal epidermis (p = 0.01). Expressed as density in the tissue, the IFN-gamma+ CD3+ cell number in psoriatic epidermis was 97+/-22 per mm2 surface area, as compared with 4.4+/-1.8 per mm2 of normal epidermis (p = 0.002). Thus, the total number of IFN-gamma+CD3+ T cells in the skin of a patient with 20% involvement is estimated to be 3.9 x 10(8). CD4+ and CD8+ IFN-gamma+ T cells were both elevated in psoriatic epidermis (p = 0.04 and p = 0.008, respectively) relative to normal skin. In the dermis, only 44% of patients demonstrated a higher percentage of IFN-gamma-producing T cells than did normals (p = 0.1), possibly indicating dilution, in some patients, by fresh infiltrating T cells. Interleukin-4 was not found by a combination of flow cytometry, reverse transcriptase-polymerase chain reaction, western blot, and immunoprecipitation. In conclusion, a significant portion of lesional T cells in psoriasis are IFN-gamma producing, without interleukin-4. The increased numbers of both IFN-gamma+CD4+ and IFN-gamma+CD8+ T cells indicate that both CD4+ and CD8+ IFN-gamma+ T cells are present in appropriate anatomic locations to sustain the lesional pathology.

[1]  J. Voorhees,et al.  Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. , 1998, The Journal of clinical investigation.

[2]  Y. Ullmann,et al.  T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. , 1997, The Journal of investigative dermatology.

[3]  S. Ziegler,et al.  The repertoire of T cell antigen receptor beta-chain variable regions associated with psoriasis vulgaris. , 1997, The Journal of investigative dermatology.

[4]  J. Breuer,et al.  Active psoriasis and profound CD4+ lymphocytopenia , 1997, The British journal of dermatology.

[5]  J. Voorhees,et al.  Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. , 1997, The Journal of clinical investigation.

[6]  T. Zollner,et al.  Induction of psoriasiform inflammation by a bacterial superantigen in the SCID‐hu xenogeneic transplantation model , 1997, Journal of cutaneous pathology.

[7]  B. Nickoloff,et al.  Dermal injection of immunocytes induces psoriasis. , 1996, The Journal of clinical investigation.

[8]  J. Strominger,et al.  T cell subsets in normal human epidermis. , 1996, The American journal of pathology.

[9]  S. Atamas,et al.  An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation. , 1996, Journal of immunology.

[10]  A. Gottlieb,et al.  Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells , 1995, The Journal of experimental medicine.

[11]  V. Maino,et al.  Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. , 1995, Blood.

[12]  J. Voorhees,et al.  Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. , 1995, The Journal of investigative dermatology.

[13]  James G. Krueger,et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.

[14]  J. Voorhees,et al.  Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. , 1995, The Journal of clinical investigation.

[15]  A. Menssen,et al.  T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells , 1994, European journal of immunology.

[16]  D. Carlo,et al.  CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Onuma,et al.  Immunohistochemical Studies of Infiltrating Cells in Early and Chronic Lesions of Psoriasis , 1994, The Journal of dermatology.

[18]  W. Jochum,et al.  T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.

[19]  M. Yamamura,et al.  The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. , 1993, The Journal of investigative dermatology.

[20]  J. Voorhees,et al.  Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis , 1993, The Journal of experimental medicine.

[21]  P. Kalinski,et al.  Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. , 1993, Journal of immunology.

[22]  J. Garioch,et al.  Group A streptococcal antigen‐specific T lymphocytes in guttate psoriatic lesions , 1993, The British journal of dermatology.

[23]  D. Leung,et al.  A potential role for superantigens in the pathogenesis of psoriasis. , 1993, The Journal of investigative dermatology.

[24]  L. Fry,et al.  The immunology of psoriasis , 1992, The British journal of dermatology.

[25]  L. Fry,et al.  Autoreactive proliferative responses by T-cell lines isolated from psoriatic lesions. , 1991, The Journal of investigative dermatology.

[26]  O. Braun-falco,et al.  Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis , 1991, The Lancet.

[27]  J. Voorhees,et al.  Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. , 1991, The Journal of investigative dermatology.

[28]  V. Dixit,et al.  Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. , 1991, Journal of dermatological science.

[29]  A. Menter,et al.  Characterization of skin-infiltrating lymphocytes in patients with psoriasis. , 1991, The Journal of investigative dermatology.

[30]  J. Voorhees,et al.  Effects of cyclosporine on immunologic mechanisms in psoriasis. , 1990, Journal of the American Academy of Dermatology.

[31]  T. Minagawa,et al.  Immunohistopathologic studies in the development of psoriatic lesion influenced by gamma-interferon and the producing cells. , 1990, Journal of dermatological science.

[32]  M. Duvic,et al.  Immunology of AIDS related to psoriasis. , 1990, The Journal of investigative dermatology.

[33]  James T. Elder,et al.  UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. , 1990, The Journal of investigative dermatology.

[34]  G. Rassner,et al.  Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. , 1990, Archives of dermatology.

[35]  D. Macdonald,et al.  T‐cell inducer populations in cutaneous inflammation: a predominance of T helper‐inducer lymphocytes (THi) in the infiltrate of inflammatory dermatoses , 1990, The British journal of dermatology.

[36]  James T. Elder,et al.  Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor‐α production in keratinocytes cultured from psoriatic lesions , 1989, The British journal of dermatology.

[37]  B. Weinshenker,et al.  Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. , 1989, Journal of the American Academy of Dermatology.

[38]  J. Voorhees,et al.  Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. , 1989, Journal of the American Academy of Dermatology.

[39]  J. Voorhees,et al.  Gamma interferon induces different keratinocyte cellular patterns of expression of HLA‐DR and DQ and intercellular adhesion molecule‐I (ICAM‐I) antigens , 1989, The British journal of dermatology.

[40]  H. Valdimarsson,et al.  An Altered Response by Psoriatic Keratinocytes to Gamma Interferon , 1988, Scandinavian journal of immunology.

[41]  A. Gottlieb,et al.  Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques , 1988, The Journal of experimental medicine.

[42]  H. Valdimarsson,et al.  A prospective study of the Koebner reaction and T lymphocytes in uninvolved psoriatic skin. , 1988, Acta dermato-venereologica.

[43]  P. Das,et al.  The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. , 1987, The Journal of investigative dermatology.

[44]  J. Billings,et al.  Cyclosporine improves psoriasis in a double-blind study. , 1986, JAMA.

[45]  C. Griffiths,et al.  Clearance of psoriasis with low dose cyclosporin. , 1986, British medical journal.

[46]  H. Valdimarsson,et al.  Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytes. , 1986, Immunology today.

[47]  C. Griffiths,et al.  Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. , 1985, Clinical and experimental immunology.

[48]  E. Christophers,et al.  Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. , 1985, Journal of the American Academy of Dermatology.

[49]  P. Biberfeld,et al.  Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor/cytotoxic T cells in epidermis during the evolution of the lesion. , 1984, The Journal of investigative dermatology.

[50]  T. Merigan,et al.  Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[51]  T. Merigan,et al.  Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. , 1984, The Journal of investigative dermatology.

[52]  H. Valdimarsson,et al.  Epidermal T lymphocytes and HLA‐DR expression in psoriasis , 1984, The British journal of dermatology.

[53]  W. Solbach Brief Definitive Report TUMOR-PROMOTING PHORBOL ESTERS SELECTIVELY ABROGATE THE EXPRESSION OF THE T4 DIFFERENTIATION ANTIGEN EXPRESSED ON NORMAL AND MALIGNANT (SI),ZARY) T HELPER LYMPHOCYTES* , 2003 .

[54]  V. Morhenn,et al.  Expression of HLA-DR antigen in skin from patients with psoriasis. , 1982, The Journal of investigative dermatology.

[55]  O. Braun-falco,et al.  Initial events in psoriasis: quantitative assessment * , 1973, The British journal of dermatology.